Wells Fargo’s Sarepta Therapeutics SRPT Stock Holding History

Wells Fargo’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-55,000	Closed	-$5.3M	–	7699
2023 Q4	$5.3M	Hold	55,000	–	–	﹤0.01%	2177
2023 Q3	$6.67M	Buy	55,000 +46,100	+518%	+$5.21M	﹤0.01%	1903
2023 Q2	$1.02M	Hold	8,900	–	–	﹤0.01%	3463
2023 Q1	$1.23M	Hold	8,900	–	–	﹤0.01%	3237
2022 Q4	$1.15M	Buy	+8,900	New	+$1.03M	﹤0.01%	3161
2021 Q2	–	Sell	-13,600	Closed	-$1.01M	–	7404
2021 Q1	$1.01M	Sell	13,600 -6,200	-31%	-$572K	﹤0.01%	4237
2020 Q4	$436K	Buy	19,800 +10,700	+118%	+$1.59M	﹤0.01%	4615
2020 Q3	$264K	Buy	+9,100	New	+$1.38M	﹤0.01%	4797
2019 Q3	–	Sell	-3,200	Closed	-$2K	–	6698
2019 Q2	$2K	Buy	+3,200	New	+$389K	﹤0.01%	6181

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wells Fargo's SRPT Position: Q2 2026 in Review

Wells Fargo increased its Sarepta Therapeutics (SRPT) stake by 74% in Q2 2026, buying an estimated $1.78M and bringing the position to 221,081 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #3054.

Wells Fargo first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $113M in Q4 2020. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Wells Fargo held 221,081 shares of Sarepta Therapeutics worth $3.97M as of Q2 2026.
Wells Fargo bought 93,881 Sarepta Therapeutics shares in Q2 2026, an estimated $1.78M.
Sarepta Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3054 holding.
Wells Fargo first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
Wells Fargo's Sarepta Therapeutics position peaked at $113M in Q4 2020.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.